Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

11.87 +0.56 (+5.00%)
Streaming Delayed Price Updated: 11:09 AM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Entrada Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next. 
Via The Motley Fool
News headline image
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock ↗
 
Via Benzinga
News headline image
Recap: Entrada Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Entrada (TRDA) Q2 Revenue Drops 98% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Entrada Therapeutics Inc (NASDAQ:TRDA) Reports Q2 2025 Earnings Miss, Shares Drop in Pre-Market Trading ↗
Entrada Therapeutics (TRDA) missed Q2 2025 revenue and EPS estimates, posting $1.95M revenue vs. $9.84M expected and a $1.04 loss per share. Shares fell 2% pre-market amid investor concerns. Pipeline... 
Via Chartmill
Topics Earnings
News headline image
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy ↗
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne muscular dystrophy patients. 
Via Benzinga
News headline image
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Insiders Buying America's Car-Mart And 2 Other Stocks ↗
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying ↗
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
News headline image
HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today? ↗
Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Sabre Are Trading Lower By 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Jumps 150 Points; Crude Oil Rises 1% ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Edges Lower; Gold Rises 1.5% ↗
U.S. stocks traded mixed midway through trading, with the S&P 500 and the Nasdaq Composite moving lower on Tuesday. 
Via Benzinga
News headline image
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who... 
Via Benzinga
News headline image
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Why Entrada Therapeutics Shares Are Trading Lower By 32%; Here Are 31 Stocks Moving Premarket ↗
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with small... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.